A weekly health led newsletter grounded in evidence-based medicine along with prospective randomized controlled trials (RCTs) by medical specialists. Our goal is to help you make sense of complex scientific information and turn it into clear, evidenced based practices you can use to make better decisions about your health and wellness.

In 2017 a Cornell team ran an experiment that should not have worked. They clamped both renal arteries in rats for 45 minutes, then waited a full month while scarring set in. Only then did they start treatment.

Six weeks of a four-amino-acid peptide. The fibrosis stopped. Podocyte architecture came back.

Then the protection was held for at least six months after the drug was withdrawn. Szeto et al., JASN 2017.

Those were rats, and we will keep saying so. But drugs are not supposed to work when you start them a full month late, and they are certainly not supposed to keep working for half a year after you stop taking them.

[PRECLINICAL / ANIMAL]  Sprague-Dawley rats, nine-month study

THE 60-SECOND VERSION

THE PROBLEM

The kidneys are about half a percent of your body weight and take 7 to 10 percent of the oxygen you burn at rest. Filtration is not what costs that much. Reabsorption is.

The proximal tubule drags sodium, glucose, and amino acids back out of the filtrate against steep gradients, all day. It is dense with mitochondria and carries almost no glycolytic reserve. When oxygen drops, it has nothing to switch to.

So acute kidney injury is both common and quiet. It touches roughly one in five hospitalized adults and has no approved treatment to date.

Part of that is diagnostic. We define the injury by a rise in creatinine among other factors, a number that only moves 24 to 48 hours after the tubules have already been damaged. Every drug tested so far arrived after the fire.

The damage does not stay in the past either. People who survive an episode carry roughly three times the risk of progressing to chronic kidney disease.

More than one in seven US adults already have it. As many as nine in ten do not know.

THE MECHANISM

Here is the part that usually gets skipped, and it is the entire reason this molecule exists.

Restoring blood flow should solve an oxygen problem. Often it does not. Ischemia physically destroys the cristae, the folded inner membranes where ATP is manufactured, so oxygen arrives back at a factory with no production line left standing.

Call it the restart problem. The tissue is not dying from what it lost during the blockage. It is dying from its inability to rebuild afterwards.

Cardiolipin is the fat that makes those folds. It exists nowhere else in the cell, and it also holds Cytochrome C, the protein that carries electrons down the chain.

Under stress, cardiolipin oxidizes. When it does, it grips cytochrome c so tightly that the protein unfolds and changes profession. The electron courier becomes a peroxidase and starts burning the membrane it is sitting on.

SS-31 binds cardiolipin and shields the Iron at the center of Cytochrome C, which stops that switch from ever flipping (Birk et al., JASN 2013). It does not mop up free radicals. It disables the machine that makes them.

Which explains the strangest property in the literature. The peptide does almost nothing to healthy mitochondria. A splint does nothing to a bone that is not broken.

[MECHANISTIC / IN VITRO] plus rat tissue

THE PATTERN

Barth syndrome is caused by a mutation in TAZ, the gene that builds mature cardiolipin. The defect is cardiolipin itself. That is the one place this drug got approved.

Heart failure, heart attack, and primary mitochondrial myopathy are not cardiolipin diseases. MMPOWER-3 enrolled 218 patients and produced Class I evidence of no benefit on walking distance or fatigue at 24 weeks.

The tidy conclusion is that this works only when cardiolipin is the root genetic defect. We think that conclusion is too summative, and the evidence already argues against it.

The same compound slowed structural progression in dry macular degeneration, which is age-related and multifactorial. Independent labs with no financial tie to the inventor have replicated podocyte rescue in diabetic models.

A better rule fits the data. It works where cardiolipin peroxidation sits early in the chain rather than at the end. In ischemia it sits early, which is the strongest argument for the kidney anyone has.

There has been one serious human test. In a randomized, double-blind, placebo-controlled pilot, fourteen patients undergoing renal artery stenting received Elamipretide or placebo during the procedure. Kidney oxygen held up better at 24 hours, and filtration improved at three months.

Fourteen people. Six on the drug. A signal worth funding, not a result worth acting on.

The biology does move in living humans, though. In 39 adults aged 60 to 85 with measurably poor muscle mitochondria, a single two-hour infusion raised peak ATP production against placebo.

The effect faded by day seven and did not improve fatigue. The mechanism is real. The schedule for using it is not solved.

THE TWIST

Elamipretide concentrates in the kidneys more than in any other tissue, and roughly 100 percent of a dose leaves in the urine within 48 hours.

The approved label already handles it. Adults with an eGFR under 30 who are not on dialysis take half the standard dose, because the metabolites accumulate once the filter is failing.

That is a trial design problem rather than a biology problem, which is a far better place to be stuck.

One naming note. SS-31, MTP-131, Bendavia, Elamipretide, and Forzinity are five names for one molecule. That is how a shelved heart drug and an approved rare-disease therapy end up being sold to you as the same longevity peptide.

READER PULSE

SOURCES AND EVIDENCE TIERS

Szeto HH et al. Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1beta and IL-18 and arrests CKD. J Am Soc Nephrol 2017;28(5):1437-1449. PMID 27881606. [PRECLINICAL / ANIMAL]

Birk AV et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 2013;24(8):1250-1261. PMID 23813215. [MECHANISTIC / IN VITRO]

Saad A et al. Phase 2a clinical trial of mitochondrial protection (elamipretide) during stent revascularization in patients with atherosclerotic renal artery stenosis. Circ Cardiovasc Interv 2017;10(9):e005487. [HUMAN RCT, PILOT, n equals 14]

Karaa A et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology 2023. PMID 37268435. [HUMAN RCT, n equals 218]

Roshanravan B et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One 2021;16(7):e0253849. PMID 34264994. [HUMAN RCT, n equals 39]

See EJ et al. Long-term risk of adverse outcomes after acute kidney injury. Kidney Int 2019;95(1):160-172. PMID 30119992. Adjusted HR for CKD 2.67. [REVIEW / META-ANALYSIS]

Heerspink HJL et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436-1446. PMID 32970396. [HUMAN RCT, n equals 4304]

US FDA. FORZINITY (elamipretide) prescribing information, 2025. [REGULATORY DOCUMENT]

Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. [INSTITUTIONAL]

The Wellness Ledger is educational and is not medical advice. Talk to your clinician before changing anything about your care.